Abstract: Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

Abstract: Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc.; R3? is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.

Abstract: An electrolyte is disclosed, for example for use in a capacitor or in a battery. An electrolyte comprises a polysaccharide matrix; and carbon nanotubes embedded within the polysaccharide matrix. Further, apparatus comprising the electrolyte is disclosed. A method of manufacturing an electrolyte is disclosed. According to the method a polysaccharide solution is provided; carbon nanotubes are suspended within the polysaccharide solution; and the polysaccharide solution is dehydrated to obtain a gel.

Abstract: A magnetic device may include a magnetic structure, a device structure, and an associated circuit. The magnetic structure may include a patterned layer of material having a predetermined magnetic property. The patterned layer may be configured to, e.g., provide a magnetic field, sense a magnetic field, channel or concentrate magnetic flux, shield a component from a magnetic field, or provide magnetically actuated motion, etc. The device structure may be another structure of the device that is physically connected to or arranged relative to the magnetic structure to, e.g., structurally support, enable operation of, or otherwise incorporate the magnetic structure into the magnetic device, etc. The associated circuit may be electrically connected to the magnetic structure to receive, provide, condition or process of signals of the magnetic device.

Abstract: Examples described herein relate to transitioning a playback session between portable playback devices such as “smart” headphones, earbuds, and handheld speakers with playback devices of a zone-based media playback system. Exemplary techniques facilitate continuity of playback when transitioning between locations (e.g., from at home to on-the-go or vice versa) or between listening paradigms (e.g., personal or out-loud playback of audio content). An example implementation includes detecting a swap trigger, determining the source playback device(s) and target playback device(s), and performing a playback session swap between the source playback device(s) and target playback device(s).

Abstract: An aerated food product includes a base ingredient, a protein and a liquid and, in some instances, a carbohydrate source. The base ingredient may include a whole grain source, a fiber source, a fruit source, a vegetable source, or a combination thereof. In some aspects, the product has a moisture content in the range of about 1% to about 5%. In one embodiment, the product has a density in the range of about 0.02 g/cc to about 0.50 g/cc. In some embodiments the product has a porosity in the range of about 15% to about 65%. In some embodiments, the product has a texture hardness in the range of about 1 kg to about 7 kg.

Abstract: The present invention relates to a mortar or concrete material comprising cement, water, fine aggregate and coarse aggregate, wherein the fine aggregate is partially replaced by metallic mineral extraction residues (MMERs) not subjected to thermal treatment, with a pH of less than 7, with a particle size of less than 4 mm, and partially stabilised with limestone material that comprises at least 60% calcite with a particle size of less than 63 ?m. The present invention also relates to the method for preparing said material and the use thereof to prepare construction materials.

Abstract: Method for obtaining biodegradable polyesteretheramide that has a stage of esterification and/or transesterification and amidation reaction, a stage of prepolycondensation, a stage of polycondensation, an optional stage of extraction, a stage of drying and a final stage of extrusion with additives. The method of obtaining PEEA enables better satisfaction of the needs of each client as regards viscosity, composition and additives. It enables reducing the amount of interface product that has lower commercial value and improves the colour of the product, while at the same time provides a more efficient process, ecologically cleaner and safer for all the operatives.

Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.

Abstract: The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl 10 (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacrylamide to a cysteine or other sulfur group.

Abstract: A magnetic device may include a magnetic structure, a device structure, and an associated circuit. The magnetic structure may include a patterned layer of material having a predetermined magnetic property. The patterned layer may be configured to, e.g., provide a magnetic field, sense a magnetic field, channel or concentrate magnetic flux, shield a component from a magnetic field, or provide magnetically actuated motion, etc. The device structure may be another structure of the device that is physically connected to or arranged relative to the magnetic structure to, e.g., structurally support, enable operation of, or otherwise incorporate the magnetic structure into the magnetic device, etc. The associated circuit may be electrically connected to the magnetic structure to receive, provide, condition or process of signals of the magnetic device.

Abstract: A gold(III) complex, a conjugate of the gold(iII) complex, a pharmaceutical composition comprising the gold(III) complex and uses and a process for preparing the gold(III) complex. The complex comprises a group of (S?C)-cyclometallated gold(III) complexes containing a 1,1-dithio ligand, which exhibit antibacterial activity against multiresistant microorganisms or against biofilm activity or biofilm disruption. The gold(III) complex has efficacy against a variety of microorganisms and low toxicity.

Abstract: A tool coupling includes a first tool part and a second tool part, the second tool part being movable in relation to the first tool part. The tool coupling further includes a first base part for detachably retaining the first tool part and a second base part movable in relation to the first base part for detachably retaining the second tool part. The first base part has a pusher movable in relation to the first base part for detaching the first tool part and the second base part has a cap movable in relation to the second base part for detaching the second tool part.

Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.

Abstract: Method for obtaining biodegradable polymers that has a stage of esterification and/or transesterification and amidation reaction, a stage of prepolycondensation, a stage of polycondensation, a stage of extraction and a stage of drying, eliminating the use of chain extenders. The polymer can achieve all the range of viscosities desired and with an improved colour compared to the polymer from other methods, where chain extenders are used, provide a more efficient process, that is environmentally cleaner and safer for the operatives.

Abstract: Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B—)p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.

Abstract: Alkylene oxides are polymerized in a tubular reactor. The alkylene oxide is continuously introduced into the tubular reactor through multiple introduction points located along the length of the tubular reactor. Monomer flow rates are increased along the length of the reactor to maintain a nearly constant concentration of unreacted alkylene oxide.

Abstract: Conversation flow is adapted based on user interactions in a cognitive interaction between a user and a machine carried out at a gateway to a cognitive interaction service. A series of cognitive interactions are received during a conversation flow. A determination is made that a pattern of user cognitive interactions meets a defined pattern and that a plurality of machine responses meets a defined threshold of a maximum repetition of responses to the defined pattern. An indication is provided to the cognitive interaction service to adapt a type of subsequent response according to a defined action for the defined pattern.

Abstract: The present invention provides a new process for stabilizing the particle size of micronized glycopyrronium salt (such as glycopyrronium bromide) which yields a micronized product exhibiting improved chemical and polymorphic stability even after prolonged storage. The invention also relates to compositions comprising said stabilized glycopyrronium salt (such as glycopyrronium bromide) and to dry powder inhaler devices and capsules or blisters comprising the stabilized glycopyrronium salt (such as glycopyrronium bromide). The glycopyrronium salt (such as glycopyrronium bromide) or compositions of the invention may be used as a medicament, for instance in the treatment of asthma, chronic obstructive pulmonary disease or cystic fibrosis or related diseases.

Abstract: The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f).